Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimers disease (AD). This population often has numerous comorbidities and is treated with multiple medications, which leads to polypharmacy. Possible pharmacokinetic and pharmacodynamic drug interactions may occur with this type of concomitant treatment, such as interactions with antipsychotics, antidepressants, anticholinergics, and cardiovascular and urinary disorder medications. Drug interactions should always be considered to reduce the risk of side effects and other problems for patients and also to increase the effectiveness of therapeutic drugs for AD.
Key words: Cholinesterase inhibitors, drug interaction, Alzheimers disease, polypharmacy
|
